Induction of eEF2-specific antitumor CTL responses in vivo by vaccination with eEF2-derived 9mer-peptides

Nakajima,Hiroko; Murakami,Yui; Morii,Eiichi; Akao,Toshiki; Tatsumi,Naoya; Odajima,Satoko; Fukuda,Mari; Machitani,Takao; Iwai,Miki; Kawata,Sayo; Hojo,Nozomi; Oka,Yoshihiro; Sugiyama,Haruo; Oji,Yusuke

doi:10.3892/or.2016.4589

Induction of eEF2-specific antitumor CTL responses in vivo by vaccination with eEF2-derived 9mer-peptides

Authors:
- Hiroko Nakajima
- Yui Murakami
- Eiichi Morii
- Toshiki Akao
- Naoya Tatsumi
- Satoko Odajima
- Mari Fukuda
- Takao Machitani
- Miki Iwai
- Sayo Kawata
- Nozomi Hojo
- Yoshihiro Oka
- Haruo Sugiyama
- Yusuke Oji
View Affiliations

Affiliations: Department of Cancer Immunology, Osaka University Graduate School of Medicine, Osaka, Japan, Department of Functional Diagnostic Sciences, Osaka University Graduate School of Medicine, Osaka, Japan, Department of Pathology, Osaka University Graduate School of Medicine, Osaka, Japan, Department of Cancer Immunotherapy, Osaka University Graduate School of Medicine, Osaka, Japan, Department of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, Osaka, Japan
Published online on: January 22, 2016 https://doi.org/10.3892/or.2016.4589
Pages: 1959-1966

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Eukaryotic elongation factor 2 (eEF2) is an essential factor for protein synthesis. Previous studies have shown that the eEF2 gene was overexpressed and plays an oncogenic role in various types of cancers and that eEF2 gene product elicited both humoral immune responses to produce eEF2-specific IgG autoantibody in cancer-bearing individuals and cellular immune responses to induce eEF2 peptide-specific cytotoxic T lymphocytes (CTLs) in vitro. The purpose of the present study was to induce eEF2-specific, antitumor CTL responses in vivo by vaccination with MHC class I-binding eEF2-derived peptide. First, two mouse MHC class I-restricted eEF2‑derived, 9-mer peptides, EF17 (17-25 aa, ANIRNMSVI) and EF180 (180-188 aa, RIVENVNVI) were identified as eEF2-specific CTL peptides, and mice were vaccinated intradermally eight times with either EF17 or EF180 peptide emulsified with Montanide ISA51 adjuvant. Cytotoxicity assay showed that eEF2-specific CTLs were induced in both EF17‑and EF180‑vaccinated mice, and histological study showed no detectable damage in the organs of these mice. Next, to examine in vivo antitumor effects of eEF2 peptide vaccination in a therapeutic model, mice were vaccinated four times with one each of the two eEF2 peptides at weekly intervals after implantation of eEF2-expressing leukemia cells. The vaccination with eEF2 peptides induced eEF2-specific CTLs and suppressed tumor growth, and disease-free survival was significantly longer in EF180-vaccinated mice compared to control mice. The survival was associated with the robustness of eEF2-specific CTL induction. These results indicate that vaccination with MHC class I-binding eEF2 peptide induced eEF2-targeting, antitumor CTL responses in vivo without damage to normal organs, which provided us a rationale for eEF2 peptide-based cancer immunotherapy.

View Figures

View References

1	Madorsky Rowdo FP, Baron A, Urrutia M and Mordoh J: Immunotherapy in cancer: A combat between tumors and the immune system; you win some, you lose some. Front Immunol. 6:1272015. View Article : Google Scholar : PubMed/NCBI
2	Ott PA, Hodi FS and Robert C: CTLA-4 and PD-1/PD-L1 blockade: New immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 19:5300–5309. 2013. View Article : Google Scholar : PubMed/NCBI
3	Cranmer LD and Hersh E: The role of the CTLA4 blockade in the treatment of malignant melanoma. Cancer Invest. 25:613–631. 2007. View Article : Google Scholar : PubMed/NCBI
4	Sarnaik AA and Weber JS: Recent advances using anti-CTLA-4 for the treatment of melanoma. Cancer J. 15:169–173. 2009.PubMed/NCBI
5	Tsai KK, Zarzoso I and Daud AI: PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother. 10:3111–3116. 2014. View Article : Google Scholar
6	Anagnostou VK and Brahmer JR: Cancer immunotherapy: A future paradigm shift in the treatment of non-small cell lung cancer. Clin Cancer Res. 21:976–984. 2015. View Article : Google Scholar : PubMed/NCBI
7	Guibert N, Delaunay M and Mazières J: Targeting the immune system to treat lung cancer: Rationale and clinical experience. Ther Adv Respir Dis. 9:105–120. 2015. View Article : Google Scholar : PubMed/NCBI
8	Monjazeb AM, Zamora AE, Grossenbacher SK, Mirsoian A, Sckisel GD and Murphy WJ: Immunoediting and antigen loss: Overcoming the achilles heel of immunotherapy with antigen non-specific therapies. Front Oncol. 3:1972013. View Article : Google Scholar : PubMed/NCBI
9	Kim JE and Lim M: The role of checkpoints in the treatment of GBM. J Neurooncol. 123:413–423. 2015. View Article : Google Scholar : PubMed/NCBI
10	Howell M, Lee R, Bowyer S, Fusi A and Lorigan P: Optimal management of immune-related toxicities associated with check-point inhibitors in lung cancer. Lung Cancer. 88:117–123. 2015. View Article : Google Scholar : PubMed/NCBI
11	Spahn CM, Gomez-Lorenzo MG, Grassucci RA, Jørgensen R, Andersen GR, Beckmann R, Penczek PA, Ballesta JP and Frank J: Domain movements of elongation factor eEF2 and the eukaryotic 80S ribosome facilitate tRNA translocation. EMBO J. 23:1008–1019. 2004. View Article : Google Scholar : PubMed/NCBI
12	Taylor DJ, Nilsson J, Merrill AR, Andersen GR, Nissen P and Frank J: Structures of modified eEF2 80S ribosome complexes reveal the role of GTP hydrolysis in translocation. EMBO J. 26:2421–2431. 2007. View Article : Google Scholar : PubMed/NCBI
13	Redpath NT, Price NT, Severinov KV and Proud CG: Regulation of elongation factor-2 by multisite phosphorylation. Eur J Biochem. 213:689–699. 1993. View Article : Google Scholar : PubMed/NCBI
14	Carlberg U, Nilsson A and Nygård O: Functional properties of phosphorylated elongation factor 2. Eur J Biochem. 191:639–645. 1990. View Article : Google Scholar : PubMed/NCBI
15	Gismondi A, Caldarola S, Lisi G, Juli G, Chellini L, Iadevaia V, Proud CG and Loreni F: Ribosomal stress activates eEF2K-eEF2 pathway causing translation elongation inhibition and recruitment of terminal oligopyrimidine (TOP) mRNAs on polysomes. Nucleic Acids Res. 42:12668–12680. 2014. View Article : Google Scholar : PubMed/NCBI
16	Kenney JW, Moore CE, Wang X and Proud CG: Eukaryotic elongation factor 2 kinase, an unusual enzyme with multiple roles. Adv Biol Regul. 55:15–27. 2014. View Article : Google Scholar : PubMed/NCBI
17	Verpelli C, Piccoli G, Zibetti C, Zanchi A, Gardoni F, Huang K, Brambilla D, Di Luca M, Battaglioli E and Sala C: Synaptic activity controls dendritic spine morphology by modulating eEF2-dependent BDNF synthesis. J Neurosci. 30:5830–5842. 2010. View Article : Google Scholar : PubMed/NCBI
18	Belelovsky K, Elkobi A, Kaphzan H, Nairn AC and Rosenblum K: A molecular switch for translational control in taste memory consolidation. Eur J Neurosci. 22:2560–2568. 2005. View Article : Google Scholar : PubMed/NCBI
19	Im HI, Nakajima A, Gong B, Xiong X, Mamiya T, Gershon ES, Zhuo M and Tang YP: Post-training dephosphorylation of eEF-2 promotes protein synthesis for memory consolidation. PLoS One. 4:e74242009. View Article : Google Scholar : PubMed/NCBI
20	Leprivier G, Remke M, Rotblat B, Dubuc A, Mateo AR, Kool M, Agnihotri S, El-Naggar A, Yu B, Somasekharan SP, et al: The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell. 153:1064–1079. 2013. View Article : Google Scholar : PubMed/NCBI
21	Wang X, Regufe da Mota S, Liu R, Moore CE, Xie J, Lanucara F, Agarwala U, Pyr Dit Ruys S, Vertommen D, Rider MH, et al: Eukaryotic elongation factor 2 kinase activity is controlled by multiple inputs from oncogenic signaling. Mol Cell Biol. 34:4088–4103. 2014. View Article : Google Scholar : PubMed/NCBI
22	Nakamura J, Aoyagi S, Nanchi I, Nakatsuka S, Hirata E, Shibata S, Fukuda M, Yamamoto Y, Fukuda I, Tatsumi N, et al: Overexpression of eukaryotic elongation factor eEF2 in gastrointestinal cancers and its involvement in G2/M progression in the cell cycle. Int J Oncol. 34:1181–1189. 2009.PubMed/NCBI
23	Oji Y, Tatsumi N, Fukuda M, Nakatsuka S, Aoyagi S, Hirata E, Nanchi I, Fujiki F, Nakajima H, Yamamoto Y, et al: The translation elongation factor eEF2 is a novel tumor-associated antigen overexpressed in various types of cancers. Int J Oncol. 44:1461–1469. 2014.PubMed/NCBI
24	Oka Y, Udaka K, Tsuboi A, Elisseeva OA, Ogawa H, Aozasa K, Kishimoto T and Sugiyama H: Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J Immunol. 164:1873–1880. 2000. View Article : Google Scholar : PubMed/NCBI
25	Nakajima H, Oka Y, Tsuboi A, Tatsumi N, Yamamoto Y, Fujiki F, Li Z, Murao A, Morimoto S, Hosen N, et al: Enhanced tumor immunity of WT1 peptide vaccination by interferon-β administration. Vaccine. 30:722–729. 2012. View Article : Google Scholar
26	Liu G, Ying H, Zeng G, Wheeler CJ, Black KL and Yu JS: HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res. 64:4980–4986. 2004. View Article : Google Scholar : PubMed/NCBI
27	Riker AI, Kammula US, Panelli MC, Wang E, Ohnmacht GA, Steinberg SM, Rosenberg SA and Marincola FM: Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes. Int J Cancer. 86:818–826. 2000. View Article : Google Scholar : PubMed/NCBI
28	Budhu S, Wolchok J and Merghoub T: The importance of animal models in tumor immunity and immunotherapy. Curr Opin Genet Dev. 24:46–51. 2014. View Article : Google Scholar : PubMed/NCBI
29	Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA and Yee C: Treatment of metastatic melanoma with autologous CD4⁺ T cells against NY-ESO-1. N Engl J Med. 358:2698–2703. 2008. View Article : Google Scholar : PubMed/NCBI
30	Fujiki F, Oka Y, Kawakatsu M, Tsuboi A, Tanaka-Harada Y, Hosen N, Nishida S, Shirakata T, Nakajima H, Tatsumi N, et al: A clear correlation between WT1-specific Th response and clinical response in WT1 CTL epitope vaccination. Anticancer Res. 30:2247–2254. 2010.PubMed/NCBI
31	Topalian SL: MHC class II restricted tumor antigens and the role of CD4⁺ T cells in cancer immunotherapy. Curr Opin Immunol. 6:741–745. 1994. View Article : Google Scholar : PubMed/NCBI
32	Bourgeois C and Tanchot C: Mini-review CD4 T cells are required for CD8 T cell memory generation. Eur J Immunol. 33:3225–3231. 2003. View Article : Google Scholar : PubMed/NCBI
33	Ridge JP, Di Rosa F and Matzinger P: A conditioned dendritic cell can be a temporal bridge between a CD4⁺ T-helper and a T-killer cell. Nature. 393:474–478. 1998. View Article : Google Scholar : PubMed/NCBI
34	Fujiki F, Oka Y, Tsuboi A, Kawakami M, Kawakatsu M, Nakajima H, Elisseeva OA, Harada Y, Ito K, Li Z, et al: Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1^*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes. J Immunother. 30:282–293. 2007. View Article : Google Scholar : PubMed/NCBI
35	Fujiki F, Oka Y, Kawakatsu M, Tsuboi A, Nakajima H, Elisseeva OA, Harada Y, Li Z, Tatsumi N, Kamino E, et al: A WT1 protein-derived, naturally processed 16-mer peptide, WT1, is a promiscuous helper peptide for induction of WT1-specific 332 Th1-type CD4⁺ T cells. Microbiol Immunol. 52:591–600. 2008. View Article : Google Scholar
36	Shedlock DJ and Shen H: Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science. 300:337–339. 2003. View Article : Google Scholar : PubMed/NCBI
37	Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG and Schoenberger SP: CD4⁺ T cells are required for secondary expansion and memory in CD8⁺ T lymphocytes. Nature. 421:852–856. 2003. View Article : Google Scholar : PubMed/NCBI
38	Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA, et al: Tumor-reactive CD4⁺ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 207:637–650. 2010. View Article : Google Scholar : PubMed/NCBI
39	Lin Y, Fujiki F, Katsuhara A, Oka Y, Tsuboi A, Aoyama N, Tanii S, Nakajima H, Tatsumi N, Morimoto S, et al: HLA-DPB1^*05: 01-restricted WT1332-specific TCR-transduced CD4⁺ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells. J Immunother. 36:159–170. 2013. View Article : Google Scholar : PubMed/NCBI